Background: Vulnerable plaque in coronary artery can progress to plaque rupture and thrombosis, and have a strong potential to induce acute coronary syndrome. Many studies have demonstrated that metabolic syndrome (MetS) is associated with increased risk for cardiovascular diseases and related mortalities. Methods: From September 2007 to June 2010, a total of 239 patients with stable angina pectoris (SAP) who underwent coronary angiogram and intravascular ultrasound (IVUS) were categorized into two groups: MetS group (n = 100, 56 men, 64.7 ± 9.5 years) and non-MetS group (n = 139, 98 men, 60.2 ± 8.4 years). Results: MetS group showed more frequent multivessel involvement (p = 0.026) and had more distal target vessel in coronary artery (p = 0.005) than non-MetS group, but IVUS findings showed no significant difference between the two groups. In addition, low high-density lipoprotein (HDL) cholesterol level as the criteria of MetS was observed in virtual histology (VH)-derived thin cap fibroatheroma (TCFA) group more than stable plaque group (p = 0.020), but the prevalence of MetS and other components of MetS were not different between the two groups.
Introduction
Most of the acute coronary syndromes (ACS) are thought to be the result of sudden luminal thrombosis [1] [2] [3] [4] [5] , and luminal thrombosis occurs from plaque rupture, erosion, and calcified nodules. Vulnerable plaque (VP) has been identified as a possible cause of sudden cardiac death, because VP is susceptible to sudden rupture, swiftly forming a clot that blocks the flow of blood through a coronary artery. VP is different from the fibrotic, calcified plaque that grows gradually until a lesion completely occludes an artery. It has been observed that some plaques at other sites in the coronary tree resemble the rupture plaque but lack a luminal thrombus: these lesions have been designated as thin cap fibroatheroma (TCFA) or VP [5] . The TCFA has been postulated to be the precursor lesion of plaque rupture and is most frequently observed in patients with acute plaque rupture [6] . Many studies have shown metabolic syndrome (MetS) to be a risk factor for coronary artery disease [7] [8] [9] [10] , but no data are available on the direct effect of MetS on the vulnerability of the plaque in the patients with stable angina pectoris (SAP). Virtual histology-intravascular ultrasound (VH-IVUS) can provide quantitative information on plaque composition; it has been validated in studies of explanted human coronary segments [11] .
The aim of the present study was to assess the relationship between the presence of MetS and VP in patients with SAP by using VH-IVUS.
Methods

Study population
This study was a retrospective, single-center study. From September 2007 to June 2010, we identified 239 consecutive patients with SAP who underwent coronary angiogram and VH-IVUS. The presence of SAP was determined when typical effort-induced chest pain which was relieved by resting was present, and functional studies such as treadmill test or myocardial single-photon emission computed tomography revealed findings compatible with ischemia. IVUS exam was performed in patients with intermediate coronary stenosis, which was defined as diameter stenosis 30-70% on quantitative coronary angiography (QCA), at Chonnam National University Hospital, Gwangju, Korea. Lesions examined by IVUS were the culprit lesions. Patients were divided into MetS group (n = 100) and non-MetS group (n = 139) according to the presence of MetS. We excluded patients with restenosis after stenting, coronary artery bypass graft failure, factors associated with increased risk of bleeding, severe heart failure or cardiogenic shock, important systemic disease, or serum creatinine ≥2.0 mg/dl, and patients in whom adequate IVUS images could not be obtained. The protocol was approved by the institutional review board. Hospital records of patients were reviewed to obtain clinical demographics and medical history.
Laboratory analysis
Peripheral blood samples were obtained before IVUS study using direct venipuncture. The blood samples were centrifuged, and serum was removed and stored at −70 • C until the assay could be performed. The serum levels of total cholesterol, triglyceride, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured by standard enzymatic methods. High-sensitivity C-reactive protein (CRP) was analyzed turbidimetrically with sheep antibodies against human CRP; this has been validated against the Dade-Behring method [12] . Serum N-terminal pro-B-type natriuretic peptide was measured using an electrochemiluminescence sandwich immunoassay method with an Elecsys 2010 analyzer (Roche Diagnostics, Mannheim, Germany).
Quantitative coronary angiographic analysis
Coronary angiogram was analyzed with validated QCA system (Philips H5000 or Allura DCI program, Philips Medical System, Eindhoven, the Netherlands). With the outer diameter of the contrast-filled catheter as the calibration standard, the minimal lumen diameter, reference diameter, and lesion length were measured in diastolic frames from orthogonal projections. Perfusion was evaluated according to thrombolysis in myocardial infarction (TIMI) criteria.
IVUS Imaging and analysis
All gray-scale and VH-IVUS examinations were performed after intracoronary administration of 300 g nitroglycerine. A 20-MHz, 2.9F IVUS imaging catheter (Eagle Eye, Volcano Corp, Rancho Cordova, CA, USA) was advanced >10 mm beyond the lesion; and automated pullback was performed to a point >10 mm proximal to the lesion at a speed of 0.5 mm/s. IVUS data were analyzed by 2 independent observers (H.Y.J and C.Y.H). The levels of reproducibility for external elastic membrane (EEM), lumen, and plaque plus media (P&M) cross-sectional areas (CSAs) using the Spearman rank-order correlation coefficients were 0.96, 0.97, and 0.97, respectively. Similarly, for plaque components by VH-IVUS, reproducibility for the fibrous (FT), fibro-fatty (FF), dense calcium (DC), and necrotic core (NC) volume measurements using the Spearman rank-order correlation coefficients were 0.93, 0.94, 0.93, and 0.93, respectively. Quantitative volumetric gray-scale and VH-IVUS analysis were performed across the entire lesion segment, and cross-sectional analysis was performed at the minimum lumen sites and at the largest NC sites.
Conventional quantitative volumetric gray-scale IVUS analysis was performed according to the American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies [13] . Measurements were made by every 1-mm interval for the region of interest, which was defined as the segment between distal to proximal reference sites that were the most normal looking 10 mm proximal and distal to the lesion. Volumetric data were generated by the software using Simpson's method. EEM and lumen CSA were measured. P&M CSA was calculated as EEM minus lumen CSA; and plaque burden was calculated as P&M divided by EEM CSA. Hypoechoic plaque was less bright than the adventitia, hyperechoic noncalcified plaque was as bright as or brighter than the adventitia without acoustic shadowing, and hyperechoic calcified plaque was brighter than the adventitia with acoustic shadowing. When there was no dominant plaque component, we classified it as mixed plaque.
VH-IVUS analysis classified the color-coded tissue into four major components: green (FT); yellow-green (FF); white (DC); and red (NC) [11, 14] . VH-IVUS analysis was reported in absolute amounts and as a percentage of plaque area or volume. TCFA was defined as focal, NC-rich (≥10% of the CSA) plaque area in at least 3 consecutive frames without overlying fibrous tissue in the presence of plaque burden ≥40% [14] .
Definition of MetS
For the diagnosis of MetS at baseline, we used the US National Cholesterol Education Program-Adult Treatment Panel (NCEP-ATP) III criteria. Central obesity was defined as waist circumference >90 cm in men or >80 cm in women by modified ATP III guideline that WHO-Western Pacific Region (WPR) and International Association for the Study of Obesity (IASO) presented for Asian populations in 2000. The presence of MetS was analyzed considering the presence of the following criteria: (1) central obesity: waist circumference >90 cm (men), >80 cm (women); (2) a fasting triglyceride level ≥150 mg/dl; (3) reduced HDL cholesterol: <40 mg/dl (men), <50 mg/dl (women); (4) hypertension: blood pressure ≥130/85 mmHg or taking antihypertensive medication; and (5) impaired fasting glucose (IFG): fasting glucose ≥100 mg/dl or taking medication or past history of type 2 diabetes mellitus (DM). Patients were considered to have MetS in the presence of ≥3 of criteria, according to the definition proposed by the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI).
Statistical analysis
The Statistical Package for Social Sciences (SPSS) for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA) was used for all analysis. Continuous variables were presented as the mean value ± 1 SD; comparisons were conducted by Student's t-test or the Wilcoxon rank-sum test if normality assumption was violated. Discrete variables were presented as percentages and frequencies; comparisons were conducted by 2 statistics or Fisher's exact test as appropriate. A multivariable logistic regression analysis was performed to identify the independent predictors of culprit lesion TCFA. A p-value <0.05 was considered statistically significant.
Results
Clinical characteristics
The baseline characteristics are summarized in Table 1 . Patients with MetS were significantly older and there were more females compared with those without MetS. Apolipoprotein (Apo) A1 was lower, but homocysteine, Apo B/A1 ratio, and glycosylated hemoglobin level were higher in the MetS group than the non-MetS group. Dyslipidemia was defined as history of dyslipidemia, not by laboratory findings during admission. Therefore, the prevalence of dyslipidemia was low. Between the two groups, no significant differences were present in the type of medications that can affect the plaque morphology.
Coronary angiographic findings
Angiographic findings are summarized in Table 2 . Multivessel disease was more common in patients with MetS compared with those without MetS. MetS group had more distal target vessel in coronary artery than non-MetS group, but less proximal target vessel than non-MetS group. There were no meaningful trends in target vessel and TIMI flow grade according to the presence of MetS.
Gray-scale IVUS results
Gray-scale IVUS results are summarized in Table 3 . There were no significant differences in gray-scale IVUS findings between the two groups, but EEM volume, lumen volume, and plaque volume tended to be greater in patients with MetS compared with those without MetS.
VH-IVUS results
At the minimum lumen site, absolute FT area was significantly greater in patients with MetS compared with those without MetS ( Fig. 1) . At the largest necrotic core site, absolute NC area was significantly greater in patients with MetS compared with those without MetS, but %NC volume was not significantly greater in patients with MetS compared to those without MetS (Fig. 2 ). Absolute FT volume was significantly greater in patients with MetS compared with those without MetS (Fig. 3 ).
Components of MetS and independent predictors of VH-derived TCFA
The relation between components of MetS and VH-derived TCFA are listed in Table 4 . VH-derived TCFA is not a frequent plaque type lesion submitted to intervention (11.7%). Only HDL cholesterol level as the criteria of MetS was observed in VH-derived TCFA group more than stable plaque group, but the prevalence of MetS and other components of MetS were not different between the two groups. The following variables were tested to determine the independent predictors of VH-derived TCFA (variables with p value <0.1 in univariate analysis): low HDL cholesterol level, proximal lesion location, left main stem disease, smoking, abundant plaque burden, old age (>65), and male gender ( Table 5 ). Multivariate analysis using logistic regression showed that the independent predictor of VH-derived TCFA is the low HDL cholesterol level (odds ratio = 3.563, 95% confidence interval = 1.370-9.269, p = 0.009).
Discussion
The major findings of this study are as follows: (1) VHderived TCFA is not a frequent plaque type lesion submitted to intervention in SAP patients; (2) MetS is not meaningfully associated with VH-derived TCFA in SAP patients; and (3) low HDL cholesterol level is the independent predictor of VH-derived TCFA as culprit lesion in SAP patients.
The high-risk atheromatous plaque, often referred to as VP, is described as TCFA, the main component of which consists of lipid-rich atheromatous core, thin fibrous cap with macrophage and lymphocyte infiltration, decreased smooth muscle cell content, and extensive remodeling of the arterial wall [15] . This combination of a large lipid core and thin fibrous cap predisposes to physical disruption of atherosclerotic plaque (i.e. endothelial erosions and fibrous cap rupture), resulting in an ACS. Intravascular plaque rupture exposes the thrombogenic lipid core and sub-endothelium to the blood, resulting in thrombosis, vascular obstruction, and possibly critical ischemia. It has been well-known that atherosclerotic plaques responsible for the majority of life-threatening syndromes are characterized by inflammation [15] [16] [17] [18] . Especially, this concept has moved the focus to new imaging techniques, such as IVUS, that can identify those lesions with an increased risk of causing an acute event in the near future. Although VH-IVUS cannot directly measure the inflammatory status of plaque, it can provide detailed qualitative and quantitative plaque information and identify four specific plaque components. MetS is rapidly increasing in frequency. Also, patients with MetS have been shown to have higher cardiovascular risk when associated with significant angiographic coronary artery disease [19] [20] [21] [22] . Considering that MetS is frequent in real-world practice, it can be an important issue to investigate whether MetS is related with VP. However, there are very limited data regarding this interrogation. Therefore, we assessed the relationship between the presence of MetS and VP in the patients with SAP by using VH-IVUS.
Several studies have demonstrated the coronary plaque components assessed by VH-IVUS in patients with ACS [23, 24] . Rodriguez-Granillo et al. reported that VH-IVUS identified TCFA as a more prevalent finding in patients with ACS compared with stable angina [14] . TCFA is the precursor of plaque rupture, which accounts for a majority of coronary thrombi and coronary death [5, 6] . In the Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) trial, VH-derived TCFA are related to future cardiovascular events, overcoming the well-known limitation of VH to detect thin fibrous cap due to lack of spatial resolution [25] . Also, Yamada et al. reported that target lesion TCFA may be related to the long-term clinical outcomes after successful percutaneous coronary intervention in patients with angina pectoris [26] . Therefore, the detection of TCFA by VH-IVUS may be important in regard to improve the prognosis of ischemic heart diseases. HDL provides the principal means by which excess cholesterol can be removed from peripheral tissues, including the foam cells of the evolving atherosclerotic plaque, and returned to the liver for catabolism or recycling [27] . At the molecular level, HDL inhibits atherosclerosis at multiple sites, including reduced adhesion of inflammatory cells to the endothelium and their migration into the arterial intima, reduced inflammation within the artery wall, and inhibition of LDL oxidation [27] . The promotion of reverse cholesterol transport by HDL implies a beneficial effect on atheroma volume, whereas the anti-inflammatory effects of HDL may promote plaque stability and reduced risk of plaque rupture. Although MetS did not predict the presence of VH-derived TCFA in patients with SAP, our study suggested that low concentrations of HDL cholesterol, but not high concentrations of LDL cholesterol, might be associated with vulnerable coronary plaque in patients with SAP. Thus, patients with low concentrations of HDL cholesterol might have a high risk of plaque rupture and thrombus formation, which can lead to ACS and even cardiac death, because of the disruption of TCFA. In contrast with our study, previous epidemiological studies have shown that long-term morbidity and mortality in coronary artery disease, manifest over years, is directly related to circulating levels of atherogenic lipoproteins, in particular LDL cholesterol [28] . Also, Kato et al. showed that high LDL cholesterol level is an independent predictor of vulnerability to coronary plaque formation in ACS patients without MetS [29] . However, the Tromsø study provided evidence for antiatherogenic effects of HDL, relating to both inhibition of plaque growth and enhanced plaque stability [30] . These findings are further extended by a recent population-based observational cohort study in the UK in 18,815 patients [31] . Also, Olsson et al. showed that plasma HDL cholesterol, but not LDL cholesterol, measured in the initial stage of ACS predicts the risk of recurrent cardiovascular events [32] . Our results suggest their finding can be applicable to the patients with SAP as well as ACS.
Low HDL cholesterol is an independent risk factor for atherothrombotic coronary events, and correction of low HDL cholesterol reduced coronary event rates significantly in a number of randomized intervention trials [33, 34] . The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) illustrated the benefits of intervening to correct the lipid profile in a patient population with low HDL cholesterol at baseline [35] , and patients with the lowest HDL cholesterol appeared to derive greatest benefits from intervention with a statin, consistent with their higher overall cardiovascular risk [36] . In our study, the observed relationship between HDL cholesterol and VH-derived TCFA raises the possibility that HDL cholesterol might be an attractive target for modifying the high-risk patient among those with SAP. Also, it is possible that the recovery of low HDL cholesterol level might be a useful indicator to assess the efficacy of such treatments for secondary prevention of cardiovascular events in SAP patients.
Study limitations
This study has several limitations. First, the present study is a retrospective single-center study, so, is subject to limitations inherent in this type of clinical investigation. Second, IVUS and VH-IVUS imaging were performed at the discretion of the individual operators, so these situations might lead to potential selection bias. Third, heavily calcified plaques may induce an artifact regarding the codification of plaques by VH-IVUS resulting in an increment of NC content. Fourth, VH-IVUS is a weak tool to detect VP. The reason for that comes from the insufficient spatial resolution of commercially available VH-IVUS, although the PROSPECT trial provided evidence that VH-derived TCFA are related to future cardiovascular events [25] . A larger and more adequately powered prospective investigation may be needed to verify the results of this study.
Conclusions
VH-derived TCFA is not a frequent plaque type lesion submitted to intervention in SAP patients, and MetS is not an independent predictor of VH-derived TCFA as culprit lesion in SAP patients.
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